TG THERAPEUTICS, INC. 8K

TG Therapeutics reported strong Q2 2026 BRIUMVI-driven results, raised 2026 revenue guidance, and highlighted key clinical and pipeline milestones supporting expanded use of BRIUMVI and related programs.

On August 3, 2026, TG Therapeutics, Inc. reported strong second quarter 2026 financial results driven by BRIUMVI, with total global revenue of approximately $240 million (including $227.7 million of U.S. net product revenue), raised its full-year 2026 total global revenue guidance to about $950 million and BRIUMVI U.S. net product revenue guidance to $890–905 million, and provided updates on its development programs, including positive Phase 3 ENHANCE topline data supporting a simplified IV initiation regimen, encouraging Phase 1 data and ongoing Phase 3 work for subcutaneous BRIUMVI, and initiation of trials in myasthenia gravis and treatment‑resistant schizophrenia, while noting it expects existing cash and projected BRIUMVI revenues to fund operations under its current plan.

Filing Facts

CIK

1001316

Ticker

TGTX

Form

8K

Source Type

fda

Accession

0001437749-26-025304

Alert Tier

7